Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Seven Former FDA Commissioners: The FDA Should Be An Independent Federal Agency.

Califf RM, Hamburg M, Henney JE, Kessler DA, McClellan M, von Eschenbach AC, Young F.

Health Aff (Millwood). 2019 Jan;38(1):84-86. doi: 10.1377/hlthaff.2018.05185.

PMID:
30615515
2.

Health, Wealth, and the 21st Century Cures Act.

Lo AW, Philipson TJ, von Eschenbach AC.

JAMA Oncol. 2016 Jan;2(1):17-8. doi: 10.1001/jamaoncol.2015.4221. No abstract available.

PMID:
26513279
3.

Expediting the availability of drugs for US patients with cancer.

Farrell AT, Pazdur R, von Eschenbach AC.

Nat Clin Pract Urol. 2008 Dec;5(12):654-6. doi: 10.1038/ncpuro1255. Review. No abstract available.

PMID:
19050708
4.

The FDA Amendments Act: reauthorization of the FDA.

von Eschenbach AC.

Food Drug Law J. 2008;63(2):579-84. No abstract available.

PMID:
18561478
5.

State of the FDA.

von Eschenbach AC.

Food Drug Law J. 2007;62(2):423-7. No abstract available.

PMID:
17632970
6.

Eliminating error-prone notations in medical communications.

von Eschenbach AC.

Expert Opin Drug Saf. 2007 May;6(3):233-4.

PMID:
17480172
7.

The Biomarkers Consortium: public and private sectors working in partnership to improve the public health.

Zerhouni EA, Sanders CA, von Eschenbach AC.

Oncologist. 2007 Mar;12(3):250-2. No abstract available.

8.

Cancer informatics vision: caBIG.

von Eschenbach AC, Buetow K.

Cancer Inform. 2007 Feb 6;2:22-4. No abstract available.

9.

Progress with a purpose: eliminating suffering and death due to cancer.

von Eschenbach AC.

Oncology (Williston Park). 2006 Nov;20(13):1691-6. No abstract available.

10.

The future of protecting and promoting public health.

von Eschenbach AC.

FDA Consum. 2006 Jan-Feb;40(1):72. No abstract available.

11.

Keynote speech: progress with a purpose.

von Eschenbach AC.

Cancer. 2005 Dec 15;104(12 Suppl):2903-4. No abstract available.

12.

A vision for the National Cancer Program in the United States.

von Eschenbach AC.

Nat Rev Cancer. 2004 Oct;4(10):820-8. doi: 10.1038/nrc1458. Review.

PMID:
15510163
13.

Andrew C. von Eschenbach, MD, director, National Cancer Institute.

von Eschenbach AC.

J Investig Med. 2004 Jan;52(1):1-5. doi: 10.1136/jim-52-01-01. No abstract available.

PMID:
14989365
14.

Introductory comments: models of anti-cancer therapy.

Von Eschenbach AC.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S1. No abstract available.

PMID:
14508074
15.

NCI sets goal of eliminating suffering and death due to cancer by 2015.

von Eschenbach AC.

J Natl Med Assoc. 2003 Jul;95(7):637-9. No abstract available.

16.

Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.

Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, McDonnell T.

Cancer. 2003 Apr 1;97(7):1630-8.

17.

Pubourethral sling simultaneous with radical retropubic prostatectomy for patients at high risk for postprostatectomy incontinence.

Pisters LL, Westney OL, Scott S, Swanson DA, Wood CG, Von Eschenbach AC, Dinney CP, McGuire EJ.

Prostate Cancer Prostatic Dis. 2000 Dec;3(S1):S34. No abstract available.

18.

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.

Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I.

Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105.

PMID:
12128107
19.

NCI remains committed to current mammography guidelines.

Von Eschenbach AC.

Oncologist. 2002;7(3):170-1. No abstract available.

20.

Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome.

Izawa JI, Madsen LT, Scott SM, Tran JP, McGuire EJ, Von Eschenbach AC, Pisters LL.

J Clin Oncol. 2002 Jun 1;20(11):2664-71.

PMID:
12039928
21.

Counseling patients about prostate cancer screening.

Foxhall LE, Von Eschenbach AC.

Am Fam Physician. 2002 May 1;65(9):1752, 1754, 1757. No abstract available.

22.

Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.

Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich ML, Pollack A.

Clin Cancer Res. 2002 May;8(5):1148-54.

23.

American Cancer Society guidelines for the early detection of cancer.

Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, Sener S, Saslow D, Eyre HJ; American Cancer Society.

CA Cancer J Clin. 2002 Jan-Feb;52(1):8-22.

24.

Lack of prostate cancer radiosensitization by androgen deprivation.

Pollack A, Salem N, Ashoori F, Hachem P, Sangha M, von Eschenbach AC, Meistrich ML.

Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1002-7. Erratum in: Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1422.

PMID:
11704324
25.

American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection.

Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C, Runowicz C, Saslow D, Cokkinides V, Eyre H; ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee, ACS Endometrial Cancer Advisory Committee.

CA Cancer J Clin. 2001 Jan-Feb;51(1):38-75; quiz 77-80. Erratum in: CA Cancer J Clin 2001 May-Jun;51(3):150.

26.

Spermatic cord sarcoma: outcome, patterns of failure and management.

Ballo MT, Zagars GK, Pisters PW, Feig BW, Patel SR, von Eschenbach AC.

J Urol. 2001 Oct;166(4):1306-10.

PMID:
11547063
27.
28.

The challenge of prostate cancer.

von Eschenbach AC.

CA Cancer J Clin. 1999 Sep-Oct;49(5):262-3. No abstract available.

29.

Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy.

Izawa JI, Perrotte P, Greene GF, Scott S, Levy L, McGuire E, Madsen L, von Eschenbach AC, Pisters LL.

J Urol. 2001 Mar;165(3):867-70. Review.

PMID:
11176488
30.

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer.

Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I.

J Clin Oncol. 2000 Dec 1;18(23):3904-11.

PMID:
11099319
31.

Major surgery to manage definitively severe complications of salvage cryotherapy for prostate cancer.

Izawa JI, Ajam K, McGuire E, Scott S, von Eschenbach AC, Skibber J, Pisters LL.

J Urol. 2000 Dec;164(6):1978-81.

PMID:
11061895
32.

External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.

Pollack A, Smith LG, von Eschenbach AC.

Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):507-12.

PMID:
10974469
33.

Correlation of non-random chromosomal aberrations in lymphocytes of prostate cancer patients with specific clinical parameters.

Ozen M, Hopwood VL, Balbay MD, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S.

Int J Oncol. 2000 Jul;17(1):113-7.

PMID:
10853027
34.

The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions.

Pollack A, Ashoori F, Sikes C, Joon DL, von Eschenbach AC, Zagars GK, Meistrich ML.

Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):153-8.

PMID:
10656387
35.

Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy.

Pisters LL, Perrotte P, Scott SM, Greene GF, von Eschenbach AC.

J Clin Oncol. 1999 Aug;17(8):2514-20.

PMID:
10561317
36.

Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy.

Khoo VS, Pollack A, Cowen D, Joon DL, Patel N, Terry NH, Zagars GK, von Eschenbach AC, Meistrich ML, Troncoso P.

Prostate. 1999 Nov 1;41(3):166-72.

PMID:
10517874
37.

Amplification of the Y chromosome in three murine tumor cell lines transformed in vivo by different human prostate cancers.

Multani AS, Ozen M, Agrawal A, Hopwood VL, von Eschenbach AC, Pathak S.

In Vitro Cell Dev Biol Anim. 1999 Apr;35(4):236-9.

PMID:
10478804
38.

Model systems of prostate cancer: uses and limitations.

Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P.

Cancer Metastasis Rev. 1998-1999;17(4):361-71. Review.

PMID:
10453280
39.

Amplification of telomeric DNA directly correlates with metastatic potential of human and murine cancers of various histological origin.

Multani AS, Ozen M, Sen S, Mandal AK, Price JE, Fan D, Radinsky R, Ali-Osman F, Von Eschenbach AC, Fidler IJ, Pathak S.

Int J Oncol. 1999 Sep;15(3):423-9.

PMID:
10427120
40.

Quality of life after salvage cryotherapy: the impact of treatment parameters.

Perrotte P, Litwin MS, McGuire EJ, Scott SM, von Eschenbach AC, Pisters LL.

J Urol. 1999 Aug;162(2):398-402.

PMID:
10411046
41.

Transrectal ultrasound-guided intraprostatic injection of absolute ethanol with and without carmustine: a feasibility study in the canine model.

Levy DA, Cromeens DM, Evans R, Stephens LC, von Eschenbach AC, Pisters LL.

Urology. 1999 Jun;53(6):1245-51.

PMID:
10367863
42.

Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome.

Liebross RH, Pollack A, Lankford SP, Zagars GK, von Eschenbach AC, Geara FB.

Cancer. 1999 Apr 1;85(7):1577-85.

PMID:
10193949
43.

Specific androgen receptor activation by an artificial coactivator.

Sui X, Bramlett KS, Jorge MC, Swanson DA, von Eschenbach AC, Jenster G.

J Biol Chem. 1999 Apr 2;274(14):9449-54.

44.

p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential.

Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ.

J Urol. 1999 Jan;161(1):304-8.

PMID:
10037428
45.

Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer.

Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, Luthra R, Logothetis C, Von Eschenbach AC, Grossman HB, Benedict WF, Batsakis JG.

Oncogene. 1999 Feb 4;18(5):1185-96.

46.

Aneuploidy index in blood: a potential marker for early onset, androgen response, and metastasis in human prostate cancer.

Ozen M, Hopwood VL, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S.

Urology. 1999 Feb;53(2):381-5.

PMID:
9933059
47.

A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer.

Pisters LL, Dinney CP, Pettaway CA, Scott SM, Babaian RJ, von Eschenbach AC, Troncoso P.

J Urol. 1999 Feb;161(2):509-14.

PMID:
9915437
48.

Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo.

Beham AW, Sarkiss M, Brisbay S, Tu SM, von Eschenbach AC, McDonnell TJ.

Int J Mol Med. 1998 Jun;1(6):953-9.

PMID:
9852630
49.

Establishment of two human prostate cancer cell lines derived from a single bone metastasis.

Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2493-500.

50.

Structural alterations of chromosome 5 in twelve human prostate cancer cell lines.

Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S.

Cancer Genet Cytogenet. 1998 Oct 15;106(2):105-9.

PMID:
9797773

Supplemental Content

Loading ...
Support Center